The Food and Drug Administration is recalling certain batches of the blood pressure drug irbesartan as prevention for a potential cancer risk due to contamination with N-Nitrosodiethylamine (NDEA), which is used as in gasoline as a stabilizer.
The International Agency for Research on Cancer lists the substance as a probable human carcinogen. Irbesartan, made by ScieGen, is prescribed to treat high blood pressure and can be used to treat kidney disease in some patients. The recalled batches are 30-count and 90-count bottles. Products can be best identified by patients as being white, oval shaped tablets debossed with SG 160; SG 161; or SG 162," the FDA's website says. Many of the ingredients in the recalled drugs come from one company in China. However, not all medicine containing irbesartan or valsartan is being recalled.
Some Irbesartan tablets manufactured by ScieGen Pharmaceuticals and labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc (GSMS) are impacted by the voluntary recall. the FDA recommends contacting a pharmacist or physician about alternate treatment. There is a generic ban pharmaceutical for products made by Zhejiang Huahi Pharmaceuticals into the U.S.